礼来公布口服GLP-1RA III期临床结果,肥胖适应症预计今年在美提交

时代财经
Aug 26

本文来源:时代财经8月26日晚间,时代财经获悉,礼来制药公布了每日一次口服小分子GLP-1受体激动剂orforglipron的III期临床试验ATTAIN-2的积极顶线结果。这一项针对合并2型糖尿病的肥胖或超重成人患者的研究显示,orforglipron的3个剂量组均达到了主要终点和所有关键次要终点,在72周时实现了显著的体重下降、具有临床意义的糖化血红蛋白(A1C)降低,及心血管风险因素的改善。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10